Purchase Order 75N93024P00857

Award Date 7/17/24
Potential Completion Date 12/31/24
Potential Value $18K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Piscataway, NJ 08854, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Genscript USA Inc., a for-profit biotechnology company based in Piscataway, New Jersey. The $164,700.00 firm fixed-price purchase order is for monoclonal antibodies and plasmids services, with a completion date of June 14, 2026. The contract does not have a set-aside designation. Genscript is a key supplier of...
This is a $164,700 firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Genscript USA Inc., a biotechnology company in Piscataway, New Jersey. The contract is for the provision of monoclonal antibodies and plasmids services to support critical research initiatives, with a period of performance through June 15, 2026. While the contract does not have a set-aside...
This federal contract award, valued at $4,263.55, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services (HHS), to Genscript USA Inc., a biotechnology company based in New Jersey. The contract is for the provision of various molecular biology products and services, including gene synthesis, gene editing, custom protein and antibody production, to support biomedical research and public health initiatives. While...
This federal contract award to Genscript USA Inc., a biotechnology company based in New Jersey, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services (HHS). The $4,196.16 firm fixed-price purchase order is for gene synthesis services. Genscript, a for-profit organization, has a history of providing a wide range of molecular biology products and services to...
This federal contract award is for a CUSTOMIZED POLYCLONAL ANTIBODY GENERATION SERVICE provided by Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract, valued at $14,932.80, was awarded on August 21, 2015 by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services (HHS). The contract does not have a set-aside designation. Genscript has...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The $9,062.13 firm fixed-price purchase order is for plasmid and recombinant protein expression services to support NIAID's biomedical research and public health initiatives. Genscript, a for-profit organization, has a history of...
This federal contract award, valued at $5,091.65, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract is for gene synthesis services and does not have a set-aside designation. Genscript USA Inc. is a well-established provider of molecular biology products and services to various federal agencies, including the National...
This federal contract award, valued at $10,420.74, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract is for the provision of custom gene synthesis services to support biomedical research and public health initiatives. Genscript USA Inc. is a prime contractor that has received numerous awards from HHS...
This contract, awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services, provides Genscript USA Inc. with $137,250.00 to deliver monoclonal antibodies and plasmid services. The firm-fixed price purchase order has an ultimate completion date of August 31, 2025. Genscript USA Inc. is a biotechnology company in Piscataway, New Jersey that specializes in molecular biology products and services for federal agencies....
The federal contract HHSN272201600094P was awarded to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The $4,035.50 Firm Fixed Price contract was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services (HHS). The contract does not have a set-aside designation. Under this contract, Genscript is providing a wide range of molecular...

This federal contract award is for $17,568 to Genscript USA Inc., a biotechnology company in Piscataway, New Jersey. The contract is with the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS). The contract is for monoclonal antibodies and plasmids services to support biomedical research and public health initiatives. While the contract does not have a set-aside designation, Genscript has received other prime and subcontract awards from NIAID, the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the U.S. Department of Agriculture (USDA), including a $1.5 million blanket purchase agreement with USDA's Animal and Plant Health Inspection Service (APHIS) for SARS-CoV-2 surrogate virus neutralization test kits. Genscript's expertise in areas like gene synthesis, protein production, and antibody development has enabled the company to support a wide range of federal agency efforts, including rapid responses to emerging infectious disease threats.

Generated 10/1/24, 12:37 PM